-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FO3dNQcXsAdHaZDlsxw2ySFDnVBEB5UXRJt7kXZm8yIIhKyQfLjFItFk7SotEpi5 CqaFsTWlYTI5jTSeAuasLw== 0001193125-08-016961.txt : 20080131 0001193125-08-016961.hdr.sgml : 20080131 20080131163117 ACCESSION NUMBER: 0001193125-08-016961 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080129 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20080131 DATE AS OF CHANGE: 20080131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AUTOIMMUNE INC CENTRAL INDEX KEY: 0000879106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133489062 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20948 FILM NUMBER: 08564939 BUSINESS ADDRESS: STREET 1: 1199 MADIA STREET CITY: PASADENA STATE: CA ZIP: 91103 BUSINESS PHONE: 6267921235 MAIL ADDRESS: STREET 1: 1199 MADIA STREET CITY: PASADENA STATE: CA ZIP: 91103 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 29, 2008

 

 

AUTOIMMUNE INC.

(Exact Name of Registrant as specified in its charter)

 

 

 

DELAWARE   0-20948   13-348-9062

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

1199 Madia Street, Pasadena, CA   91103
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (626) 792-1235

Not Applicable

(Registrant’s name or former address, if change since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 1.01 Entry into Material Definitive Agreement.

On January 29, 2008, Colloral LLC, AutoImmune’s joint venture with Deseret Laboratories, Inc., and Futurebiotics, LLC entered into an Amendment to Supply and License Agreement, having an effective date of January 15, 2008 (the “Amendment”). The Amendment amends the Supply and License Agreement between Colloral LLC and Futurebiotics, LLC dated effective as of January 10, 2007 (the “Supply Agreement”).

The Amendment extends the initial term of exclusivity that Colloral LLC has granted to Futurebiotics LLC under the Supply Agreement and the period during which Futurebiotics LLC may extend its exclusivity under certain conditions.

This description of the Amendment is qualified in its entirety by reference to the Amendment, which AutoImmune intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarterly period ending March 30, 2008. When AutoImmune files the Amendment as an exhibit to its Quarterly Report on Form 10-Q, it intends to request confidential treatment with respect to certain terms of the Amendment.

The information contained in this Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing with the Securities Exchange Commission under the Securities Exchange Act of 1934 or the Securities Act of 1933, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

AUTOIMMUNE INC.

By:

  

/s/ Robert C. Bishop

  Robert C. Bishop, Ph.D.
  President and Chief Executive Officer

Date: January 31, 2008

-----END PRIVACY-ENHANCED MESSAGE-----